Mechanistic investigations have revealed that TROJAN binds to NKRF (NF-κB inhibitor), indirectly activating transcription factors in the NF-κB signaling pathway, which is implicated in BC cell proliferation, metastasis, and endocrine therapy resistance (Devanaboyina et al., 2022). Here, NFKB1 is linked to breast cancer.